GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medicenna Therapeutics MDNA.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

0.45

+2.27%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2026

Net income

−C$18.4m

FY2017FY2026

Free cash flow

−C$35.8m

FY2017FY2026

Shareholders' equity

C$2.5m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross profit−C$77,000−C$55,000−C$5,000−C$5,000−C$38,000−C$40,000−C$7,893−C$6,818−C$9,704−C$6,487
Research and developmentC$18.2mC$15.7mC$11.8mC$9.3mC$14.7mC$10.9mC$5.9mC$3.0mC$5.1mC$4.2m
Operating income−C$23.7m−C$21.6m−C$19.7m−C$21.6m−C$22.3m−C$17.2m−C$8.2m−C$4.7m−C$7.4m−C$7.7m
Net income−C$18.4m−C$11.8m−C$25.5mC$1.5m−C$22.6m−C$17.2m−C$8.3m−C$4.7m−C$7.5m−C$7.6m
Diluted earnings per share-0.21-0.14-0.330.02-0.33-0.32-0.17-0.14-0.30-0.31

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsC$8.5mC$28.4mC$19.1mC$36.4mC$23.5mC$42.3mC$38.0mC$5.2mC$4.4mC$14.5m
Cash and short-term investmentsC$6.3mC$24.8mC$17.0mC$33.6mC$20.5mC$40.4mC$37.7mC$2.4mC$3.9mC$14.0m
Total liabilitiesC$6.0mC$9.3mC$13.9mC$7.0mC$2.6mC$4.1mC$1.8mC$2.6mC$2.2mC$7.8m
DebtC$119,000C$168,000———C$34,000C$67,314———
Shareholders' equityC$2.5mC$19.1mC$5.2mC$29.5mC$20.8mC$38.1mC$36.1mC$2.6mC$2.2mC$6.7m
Shares outstanding87m83m78m70m70m54m49m33m25m24m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−C$17.9m−C$16.5m−C$16.3m−C$12.7m−C$23.6m−C$15.3m−C$9.0m−C$8.0m−C$10.1m−C$7.3m
Capital spending−C$17.9m−C$33,000———————−C$5,385
Free cash flow−C$35.8m−C$16.5m−C$16.3m−C$12.7m−C$23.6m−C$15.3m−C$9.0m−C$8.0m−C$10.1m−C$7.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−C$17,000−C$19,000−C$16,000−C$23,000−C$19,000−C$19,000−C$21,000−C$10,000
Operating income−C$5.5m−C$7.1m−C$5.6m−C$5.5m−C$5.5m−C$5.7m−C$5.1m−C$5.5m
Net income−C$5.1m−C$4.2m−C$4.4m−C$4.9m−C$4.9mC$1.2m−C$5.2m−C$4.2m
Diluted earnings per share-0.06-0.05-0.05-0.06-0.060.01-0.07-0.05
Cash from operations−C$4.0m−C$4.0m−C$4.0m−C$4.0m−C$3.0m−C$4.0m−C$3.0m−C$5.0m
Capital spending—−C$4.0m−C$4.0m—————
Free cash flow—−C$8.0m−C$8.0m—————
Total assetsC$8.2mC$8.5mC$13.1mC$18.0mC$22.8mC$28.4mC$32.2mC$32.9m
Cash and short-term investmentsC$5.7mC$6.3mC$10.6mC$15.7mC$20.5mC$24.8mC$30.0mC$30.4m
DebtC$71,000C$65,000C$135,000C$149,000C$162,000C$168,000C$174,000C$176,000
Shareholders' equityC$1.7mC$2.5mC$6.2mC$10.2mC$14.6mC$19.1mC$17.5mC$20.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income3.1%6.6%34.8%
Net income—1.4%30.0%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-2.0-6.5-5.018.9-2.0-3.8-20.2-13.7-1.3-3.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 14-to-1 reverse split · 3 Mar 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.